AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

PrEP

FDA Advisory Committees to Examine a Number of HIV Issues in May

FDA

The U.S. Food and Drug Administration (FDA) has three important advisory committee meetings scheduled in May that may impact HIV prevention, detection, and treatment. On May 10, 2012, FDA’s Antiviral Advisory Committee will discuss expanding the indication of Truvada (emtricitabine/tenofovir disoproxil fumarate) tablet, made by Gilead Sciences, Inc., to include use for Pre-Exposure Prophylaxis (PrEP),…

Conversation from CROI: Dr. Jonathan Mermin on PrEP and an AIDS-free Generation

Mermin YouTube still

At the recent 19th Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Ron Valdiserri, Deputy Assistant Secretary of Health for Infectious Diseases, spoke with Dr. Jonathan Mermin, Director of CDC’s Division of HIV/AIDS Prevention. They discussed some of the significant findings from the conference including advances related to pre-exposure prophylaxis (PrEP) and the growing discussions…

Using Pre-Exposure Prophylaxis (PrEP) as a Prevention Tool for MSM: The Promise Comes with Challenges

Ronald Valdiserri

On Saturday, February 26th, I attended a day-long meeting organized by the Centers for Disease Control and Prevention (CDC) and hosted by the Fenway Community Health Center in Boston. The theme of the meeting was “Moving forward with PrEP Implementation.” Meeting participants included researchers involved in the original iPrEX study and other ongoing HIV prevention…

NIH-Funded Study Finds Daily Dose of Antiretroviral Drug Reduces Risk of HIV

blog.aids.gov

Today, the New England Journal of Medicine published research findings from the iPrEx study funded by the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation testing the efficacy of pre-exposure prophylaxis (PrEP). The study is a major step forward in our ability to prevent new HIV infections. The study found that…

President Obama Welcomes New HIV Prevention Research Results

blog.aids.gov

WASHINGTON, D.C. – Today, the National Institutes of Health announced findings on recent HIV prevention research.  The study finds that a daily dose of an oral antiretroviral drug taken by HIV-negative gay and bisexual men reduced the risk of acquiring HIV infection by 43.8 percent, and had even higher rates of effectiveness, up to 73…

New Announcement about PrEP from NIH

NIAID

The National Institutes of Health National Institute of Allergy and Infectious Diseases just made a significant announcement on pre-exposure prophylaxis (PrEP). I am proud to share this important update from the NIH with our blog readers. Learn more by reading this Q&A.

Interview with Ernest Hopkins and Bob Grant about Pre-exposure Prophylaxis (PrEP)

blog.aids.gov

Recently I sat down with Ernest Hopkins, Legislative Director at the San Francisco AIDS Foundation , and Bob Grant, M.D.,M.P.H. , Senior Investigator at the Gladstone Institute at University of California San Francisco , to talk about pre-exposure prophylaxis (PrEP). Here is a video from our conversation.

Future Priorities for NIAID’s HIV Prevention Research

Future Directions for NIAID HIV Research

As we begin to discuss the restructuring of NIAID’s clinical trials networks, let us first focus on the Institute’s HIV prevention research agenda. Developing new biomedical tools that can safely and effectively prevent HIV acquisition and transmission is critical to addressing the global HIV/AIDS pandemic. Currently, we are exploring several promising HIV prevention strategies that,…